Recurrent salivary gland cancer

M. Boyd Gillespie, William Greer Albergotti, David W. Eisele

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Opinion statement: Salivary gland cancer is the most diverse cancer in the body consisting of up to 24 different pathologic subtypes. Although these cancers arise within a common group of glands in the head and neck region, these diverse cancers differ substantially in clinical behavior. As a result, salivary cancers are often categorized as low, intermediate, or high-risk for recurrence and metastasis based on histopathologic subtype and tumor stage. Appropriate risk classification of a given salivary tumor provides a useful guide to the physicians who determine the appropriate treatment regimen. Low-risk tumors can be treated successfully with surgery alone, whereas intermediate and high-risk tumors often require multimodality therapy. Recurrent salivary cancer should be considered high-risk by definition, especially if previously treated with appropriate therapy, and therefore requires aggressive multimodality therapy in order to achieve adequate local control and disease-free survival.

Original languageEnglish (US)
Pages (from-to)58-70
Number of pages13
JournalCurrent Treatment Options in Oncology
Volume13
Issue number1
DOIs
StatePublished - Mar 1 2012

Fingerprint

Salivary Gland Neoplasms
Neoplasms
Therapeutics
Disease-Free Survival
Neck
Head
Neoplasm Metastasis
Physicians

Keywords

  • Recurrent salivary gland cancer
  • Recurrent salivary gland neoplasm
  • Salivary gland cancer
  • Salivary gland neoplasm
  • Salivary gland surgery
  • Salivary gland tumor

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Recurrent salivary gland cancer. / Gillespie, M. Boyd; Albergotti, William Greer; Eisele, David W.

In: Current Treatment Options in Oncology, Vol. 13, No. 1, 01.03.2012, p. 58-70.

Research output: Contribution to journalArticle

Gillespie, M. Boyd ; Albergotti, William Greer ; Eisele, David W. / Recurrent salivary gland cancer. In: Current Treatment Options in Oncology. 2012 ; Vol. 13, No. 1. pp. 58-70.
@article{0cc3d1b369284c149a82529e5380b167,
title = "Recurrent salivary gland cancer",
abstract = "Opinion statement: Salivary gland cancer is the most diverse cancer in the body consisting of up to 24 different pathologic subtypes. Although these cancers arise within a common group of glands in the head and neck region, these diverse cancers differ substantially in clinical behavior. As a result, salivary cancers are often categorized as low, intermediate, or high-risk for recurrence and metastasis based on histopathologic subtype and tumor stage. Appropriate risk classification of a given salivary tumor provides a useful guide to the physicians who determine the appropriate treatment regimen. Low-risk tumors can be treated successfully with surgery alone, whereas intermediate and high-risk tumors often require multimodality therapy. Recurrent salivary cancer should be considered high-risk by definition, especially if previously treated with appropriate therapy, and therefore requires aggressive multimodality therapy in order to achieve adequate local control and disease-free survival.",
keywords = "Recurrent salivary gland cancer, Recurrent salivary gland neoplasm, Salivary gland cancer, Salivary gland neoplasm, Salivary gland surgery, Salivary gland tumor",
author = "Gillespie, {M. Boyd} and Albergotti, {William Greer} and Eisele, {David W.}",
year = "2012",
month = "3",
day = "1",
doi = "10.1007/s11864-011-0174-0",
language = "English (US)",
volume = "13",
pages = "58--70",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Recurrent salivary gland cancer

AU - Gillespie, M. Boyd

AU - Albergotti, William Greer

AU - Eisele, David W.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Opinion statement: Salivary gland cancer is the most diverse cancer in the body consisting of up to 24 different pathologic subtypes. Although these cancers arise within a common group of glands in the head and neck region, these diverse cancers differ substantially in clinical behavior. As a result, salivary cancers are often categorized as low, intermediate, or high-risk for recurrence and metastasis based on histopathologic subtype and tumor stage. Appropriate risk classification of a given salivary tumor provides a useful guide to the physicians who determine the appropriate treatment regimen. Low-risk tumors can be treated successfully with surgery alone, whereas intermediate and high-risk tumors often require multimodality therapy. Recurrent salivary cancer should be considered high-risk by definition, especially if previously treated with appropriate therapy, and therefore requires aggressive multimodality therapy in order to achieve adequate local control and disease-free survival.

AB - Opinion statement: Salivary gland cancer is the most diverse cancer in the body consisting of up to 24 different pathologic subtypes. Although these cancers arise within a common group of glands in the head and neck region, these diverse cancers differ substantially in clinical behavior. As a result, salivary cancers are often categorized as low, intermediate, or high-risk for recurrence and metastasis based on histopathologic subtype and tumor stage. Appropriate risk classification of a given salivary tumor provides a useful guide to the physicians who determine the appropriate treatment regimen. Low-risk tumors can be treated successfully with surgery alone, whereas intermediate and high-risk tumors often require multimodality therapy. Recurrent salivary cancer should be considered high-risk by definition, especially if previously treated with appropriate therapy, and therefore requires aggressive multimodality therapy in order to achieve adequate local control and disease-free survival.

KW - Recurrent salivary gland cancer

KW - Recurrent salivary gland neoplasm

KW - Salivary gland cancer

KW - Salivary gland neoplasm

KW - Salivary gland surgery

KW - Salivary gland tumor

UR - http://www.scopus.com/inward/record.url?scp=84857657973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857657973&partnerID=8YFLogxK

U2 - 10.1007/s11864-011-0174-0

DO - 10.1007/s11864-011-0174-0

M3 - Article

C2 - 22215326

AN - SCOPUS:84857657973

VL - 13

SP - 58

EP - 70

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 1

ER -